Skip to content

Efficacy and safety of ExPress glaucoma filtration surgery in normal tension glaucoma

Efficacy and safety of ExPress glaucoma filtration surgery in normal tension glaucoma - Effect of ExPress glaucoma filtration surgery in NTG

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013243
Enrollment
45
Registered
2014-02-24
Start date
2014-03-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal tension glaucoma

Interventions

glaucoma filtration surgery with Alcon ExPress glaucoma filtration device model P50PL

Sponsors

Alcon Japan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. diagnosed as normal tension glaucoma 2. indication for ExPress glaucoma filtration surgery 3. over 20 years old age when the study agreement was obtained 4. the patients who can understand and agree with the explanatory leaflet and written informed consent verified by IRB.

Exclusion criteria

Exclusion criteria: 1. pregnant and nursing women, and woman desiring future fertility during the study period 2. angle closure and secondary glaucoma 3. subject with a history of glaucoma surgery 4. subject to receive or has received penetrating keratoprasty 5. subject to have a problem for the IOP measurement with GAT 6. diagnosed as corneal dystrophy 7. subject with a history of any ocular surgery within 6 months 8. subject with infectious or non-infectious conjunctivitis, keratitis, or uveitis in one or both eyes 9. diagnosed as severe blepharitis or dry eye 10. subject with a metal allergy 11. judged as inappropriate for study subject 12. subject attended to the other clinical trial or study within 30 days before baseline visit

Design outcomes

Primary

MeasureTime frame
IOP lowering effect evaluating IOP reduction at 3,6 and 12 months after the surgery compared to the baseline. The number of cases who have over 20% IOP reduction at 3, 6 and 12 months postoperatively.

Countries

Japan

Contacts

Public ContactSaiko Takayama

Alcon Japan Reseach development

tsunemitsu.senta@alcon.com03-6899-5054

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026